On or around 08/27/2018 (Ongoing date of last review)
Filing Date: April 05, 2018
According to the Complaint, Cancer Genetics is an emerging leader in the field of personalized medicine, offering diagnostic products and services that enable precision medicine in the field of oncology.
The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Cancer Genetics had ineffective disclosure controls and internal controls over financial reporting; and (2) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.
On August 27, 2018, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. The consolidated cases shall be identified as "In re Cancer Genetics, Inc. Securities Litigation."
Company & Securities Information
Defendant: Cancer Genetics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: CGIX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Ben Phetteplace, et al. v. Cancer Genetics, Inc., et al.
COURT: D. New Jersey
DOCKET #: 18-CV-05612
JUDGE: Hon. Esther Salas
DATE FILED: 04/05/2018
CLASS PERIOD START: 03/23/2017
CLASS PERIOD END: 04/02/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
The Rosen Law Firm (South Orange) 609 W. South Orange Avenue Suite 2P , The Rosen Law Firm (South Orange), NJ 07079 (973) 313-1887 (973) 833-0399 ·
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violation of the Federal Securities Laws